Synthesis, Structural Characterization and Catalytic Activity of Indenyl tris-N-Pyrrolyl Phosphine Complexes of Ruthenium

The synthesis, characterization and catalytic activity of new ruthenium complexes of the tris-N-pyrrolyl phosphine ligand P(pyr)3 is described. The new ruthenium complexes [RuCl(ind)(PPh3){P(pyr)3}] and [RuCl(ind){P(pyr)3}2] (ind = indenyl ligand η5-C9H7−) were synthesized in 73% and 63% isolated yield, respectively, by thermal ligand exchange of [RuCl(ind)(PPh3)2] with P(pyr)3. The electronic and steric properties of the new complexes were studied through analysis of the X-Ray structures and through cyclic voltammetry. The new complexes [RuCl(ind)(PPh3){P(pyr)3}] and [RuCl(ind){P(pyr)3}2] and the known complex [RuCl(ind)(PPh3)2}] differed only slightly in their steric properties, as seen from the comparable bond lengths and angles around the ruthenium center. The oxidation potentials of [RuCl(ind)(PPh3){P(pyr)3}] and [RuCl(ind){P(pyr)3}2] are +0.34 and +0.71 Volt vs. Cp2Fe0/+, which are substantially higher than that of [RuCl(ind)(PPh3)2] (−0.023 V), which is in accordance with the enhanced π-acidity of the P(pyr)3 ligand. The new complexes are catalytically active in the etherification of propargylic alcohols and in the first ruthenium-catalyzed formation of known and new xanthenones from propargylic alcohols and diketones (18 to 72 h at 90 °C in ClCH2CH2Cl or toluene, 1-2 mol-% catalyst, 69-22 % isolated yields)

Synthesis, Structural Characterization and Catalytic Activity of Indenyl Complexes of Ruthenium Bearing Fluorinated Phosphine Ligands

The synthesis, characterization and catalytic activity of new ruthenium complexes of fluorinated triarylphosphines is described. The new ruthenium complexes [RuCl(ind)(PPh3){P(p-C6H4CF3)3}] and [RuCl(ind)(PPh3){P(3,5-C6H3(CF3)2)3}] were synthesized in 57% and 24% isolated yield, respectively, by thermal ligand exchange of [RuCl(ind)(PPh3)2], where ind = indenyl ligand η5-C9H7−. The electronic and steric properties of the new complexes were studied through analysis of the X-ray structures and through cyclic voltammetry. The new complexes [RuCl(ind)(PPh3){P(p-C6H4CF3)3}] and [RuCl(ind)(PPh3){P(3,5-C6H3(CF3)2)3}] and the known complex [RuCl(ind)(PPh3)2}] differed only slightly in their steric properties, as seen from comparison of bond lengths and angles associated with the ruthenium center. As determined by cyclic voltammetry, the redox potentials of [RuCl(ind)(PPh3){P(p-C6H4CF3)3}] and [RuCl(ind)(PPh3){P(3,5-C6H3(CF3)2)3}] are +0.173 and + 0.370 V vs. Cp2Fe0/+, respectively, which are substantially higher than that of [RuCl(ind)(PPh3)2] (−0.023 V). After activation through chloride abstraction, the new complexes are catalytically active in the etherification of propargylic alcohols (8–24 h at 90 °C in toluene, 1–2 mol% catalyst loading, 29–61% isolated yields). As demonstrated by a comparative study for a test reaction, the three precursor complexes [RuCl(ind)(PPh3){P(p-C6H4CF3)3}], [RuCl(ind)(PPh3){P(3,5-C6H3(CF3)2)3}] and [RuCl(ind)(PPh3)2}] differed only slightly in catalytic activity

Dicarbonyl­dichloridobis(trimethyl­phosphane)iron(II)–carbonyl­dichlorido­tris(trimethyl­phosphane)iron(II)–tetra­hydro­furan (1/1/2)

The asymmetric unit of the title crystal, [FeCl2(C3H9P)3(CO)]·[FeCl2(C3H9P)2(CO)2]·2C4H8O, contains half mol­ecules of the two closely related FeII complexes lying on mirror planes and a tetra­hydro­furan solvent mol­ecule, one C atom of which is disordered over two sets of sites with site occupancy factors 0.633 (9) and 0.367 (9). In both FeII complex mol­ecules, a distorted octa­hedral coordination geometry has been observed around the Fe atoms. Weak intermolecular C—H⋯O inter­actions are observed in the crystal structure

A generator-produced gallium-68 radiopharmaceutical for PET imaging of myocardial perfusion

Lipophilic cationic technetium-99m-complexes are widely used for myocardial perfusion imaging (MPI). However, inherent uncertainties in the supply chain of molybdenum-99, the parent isotope required for manufacturing 99Mo/99mTc generators, intensifies the need for discovery of novel MPI agents incorporating alternative radionuclides. Recently, germanium/gallium (Ge/Ga) generators capable of producing high quality 68Ga, an isotope with excellent emission characteristics for clinical PET imaging, have emerged. Herein, we report a novel 68Ga-complex identified through mechanism-based cell screening that holds promise as a generator-produced radiopharmaceutical for PET MPI

(1E,3E)-1,4-Bis(4-meth­oxy­phen­yl)buta-1,3-diene

The title compound, C18H18O2, which exhibits blue emission in the solid state, is an inter­mediate in the preparation of liquid crystals and polymers. The mol­ecule is located on an inversion centre. In the crystal, mol­ecules are arranged in a herringbone motif

Diethyl 2-[(4-nitro­phen­yl)(4-phenyl-1,2,3-selenadiazol-5-yl)meth­yl]malonate

In the title compound, C22H21N3O6Se, the heterocyclic ring makes dihedral angles of 50.03 (11) and 67.75 (11)°, respectively, with the benzene and phenyl rings. The terminal C atoms of the ester groups are disordered over two positions: the site occupancies for the C atoms are 0.62 (3)/0.38 (3) and 0.48 (3)/0.52 (3). In the crystal structure, weak intra- and inter­molecular C—H⋯O inter­actions are observed

Dioxidobis(2-oxo-1,2-dihydropyridin-3-olato)­molybdenum(VI)

In the title compound, [Mo(C5H4NO2)2O2], the MoVI atom exhibits a distorted octa­hedral coordination geometry formed by two terminal oxo ligands and two monoanionic O,O-bidentate pyridinone ligands. The two terminal oxo ligands lie in a cis arrangement, the ketonic O atoms of the pyridinone ligands are coordinated trans to the oxo ligands and the deprotonated hydroxyl O atoms are located trans to each other. The crystal structure contains inter­molecular N—H⋯O hydrogen bonds, C—H⋯O contacts and face-to-face π–π stacking inter­actions with an inter­planar separation of 3.25 (1) Å

Evaluation of novel platinum(II) based AIE compound-encapsulated mesoporous silica nanoparticles for cancer theranostic application

Advanced biomedical research has established that cancer is a multifactorial disorder which is highly heterogeneous in nature and responds differently to different treatment modalities, due to which constant monitoring of therapy response is becoming extremely important. To accomplish this, different theranostic formulations have been evaluated. However, most of them are found to suffer from several limitations extending from poor resolution, radiation damage, to high costs. In order to develop a better theranostic modality, we have designed and synthesized a novel platinum(II)-based 'aggregation induced emission' (AIE) molecule (named BMPP-Pt) which showed strong intra-cellular fluorescence and also simultaneously exhibited potent cytotoxic activity. Due to this dual functionality, we wanted to explore the possibility of using this compound as a single molecule based theranostic modality. This compound was characterized using elemental analysis, NMR and IR spectroscopy, mass spectrometry and single crystal X-ray structure determination. BMPP-Pt was found to exhibit a high AIE property with emission maxima at 497 nm. For more efficient cancer cell targeting, BMPP-Pt was encapsulated into mesoporous silica nanoparticles (Pt-MSNPs) and the MSNPs were further surface modified with an anti-EpCAM aptamer (Pt-MSNP-E). Pt-MSNPs exhibited higher intracellular fluorescence compared to free BMPP-Pt, though both of them induced a similar degree of cell death via the apoptosis pathway, possibly via cell cycle arrest in the G1 phase. Anti-EpCAM aptamer modification was found to increase both cytotoxicity and intracellular fluorescence compared to unmodified MSNPs. Our study showed that EpCAM functionalized BMPP-Pt loaded MSNPs can efficiently internalize and induce apoptosis of cancer cells as well as show strong intracellular fluorescence. This study provides clues towards the development of a potential single compound based theranostic modality in future